eular recommendations for vaccination in adult patients with
Post on 12-Apr-2017
Embed Size (px)
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
By nehal hamdyEULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
The vaccination status should be assessed in the initial work-up of patients with AIIRD (no grade of evidence possible; strength of recommendation D; Delphi vote 9.50)
Vaccination in patients with AIIRD should ideally be administered during stable disease (no grade of evidence possible; strength of recommendation D; Delphi vote 8.88)
Live attenuated vaccines should be avoided whenever possible in immunosuppressed patients with AIIRD (grade of evidence IV; strength of recommendation D; Delphi vote 9.25)
Live attenuated vaccineViral:measles vaccinemumps vaccinerubella vaccineLive attenuated influenza vaccine(2009 H1N1 flu)chicken pox vaccineOral polio vaccinerotavirus vaccineyellow fever vaccineRabies vaccinesherpes zoster vaccineBacterial:BCG vaccinetyphoid vaccine
Vaccination in patients with AIIRD can be administered during the use of disease-modifying anti rheumatic drugs and tumor necrosis factor blocking agents but should ideally be administered before starting B cell depleting biological therapy (grade of evidence IIa; strength of recommendation B; Delphi vote 9.13)
The use of live vaccines is contra-indicated unless immunosuppressive are stopped at least 3 months beforehand.Salazopyrine shouldnt be given in combination with varcillea vaccine for fear of Reye syndrome.
DMARD & ANTI TNF
Azathioprine decreased the effacy influenza vaccination in patients with SLE .The combination of TNF blocking agents and MTX reduced the response to pneumococcal vaccination in patients with RA.
Rituximab Humoral responses following influenza &pneumococcal vaccination 13 months after treatment are severely decreased.
when patients are on rituximab already, vaccines are given at least 6 months after the start but 4weeks before the next course.
Patients on steroidsno contraindication to give killed vaccine.
Live vaccines must not be given to patients taking moderate or high doses of steroids for longer than 2 weeks.
There are no contra-indications to using live vaccines if: Steroid is for less than 2 weeks. Treatment is alternate day with short acting steroid. By topical application. By intra articular or soft tissue injection. Long term low dose steroids (10mg per day or less).Moderate or high dose steroid must be stopped 3 months before live vaccines can be administered.
Inactivated influenza vaccination should be strongly considered for patients with AIIRD (grade of evidence IbIII; strength of recommendation BC; Delphi vote 9.00)
Influenza vaccination has been shown to reduce mortality from pneumonia in patients with RA, SLE, and SSc (Stojanovich L.,2008)Trade name of seasonal influenza vaccineVaxigripFluarixInfluvac
23-valent polysaccharide pneumococcal vaccination (23-PPV)should be strongly considered for patients with AIIRD (grade of evidence IbIII; strength of recommendation BC; Delphi vote 8.19)
Trade name of pneumococcal vaccinePneumovax 23Prevenar 13Pneuimmune 23
Patients with AIIRD should receive tetanus toxoid vaccination in accordance to recommendations for the general population. In case of major and/or contaminated wounds in patients who received rituximab within the last 24 weeks, passive immunization with tetanus immunoglobulins should be administered (grade of evidence II;strength of recommendation BD; Delphi vote 9.19).
In patients with RA and SLE, efficacy for tetanus toxoid vaccination has been demonstrated to be comparable with healthy controls.
Herpes zoster vaccination may be considered in patients with AIIRD (grade of evidence IIIIV; strength of recommendation CD;Delphi vote 8.00)
Based on increased risk of herpes zoster in patients with rheumatological disorder.Herpes zoster vaccine has been shown to reduce herpes zoste rand post-herpetic neuralgia in patients over 60 years. However no studies have been performed in patients with AIIRD.
Human papilloma virus vaccination should be considered in selected patients with AIIRD (grade of evidence III; strength of recommendation CD; Delphi vote 8.44)
SLE patients have increased risk to develop cancer cervix 2ndry to HPV infection compared to healthy population.
In hyposplenic/asplenic patients with AIIRD infl uenza,pneumococcal, Haemophilus influenzae b and meningococcal C vaccinations are recommended (grade of evidence IV; strength of recommendation D; Delphi vote 9.50)
asplenic patients are at risk of contracting a so called overwhelming post-splenectomy infection (OPSI). OPSIis caused by encapsulated bacteria (eg, Streptococcus pneumoniae H influenzae b, Neisseria meningitidis ) and the mortality of OPSI isup to 70%.
Hepatitis A and/or B vaccination is only recommended inpatients with AIIRD at risk (grade of evidence IIIII; strength of recommendation BD; Delphi vote 9.13)
Vaccination forhepatitis A and/or B is only recommended when the risk ofcontracting these infections is increased (travel to or residence in endemic countries for hepatitis A and/or B); increased riskof exposure to hepatitis A and/or B (eg,medical profession, infected family member)
Patients with AIIRD who plan to travel are recommended to receive their vaccinations except for live attenuated vaccines which should be avoided whenever possible in immunosuppressed patients with AIIRD (no grade of evidence; strength of recommendation D; Delphi vote 9.25)
BCG vaccination is not recommended in patients with AIIRD(grade of evidence III; strength of recommendation CD;Delphi vote 9.38BCG vaccine considered to be given in juvenile arthritis 4weeks before immunosuppressives.